Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Energy drinks

    - PMLiVE

    Alnylam’s Amvuttra approved by MHRA to treat rare heart disease ATTR-CM

    The drug has been authorised to treat both wild-type and hereditary forms of the disease

    - PMLiVE

    Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target

    The companies will aim to discover and develop new therapeutics for the group of disorders

    - PMLiVE

    Alnylam shares phase 3 results for Amvuttra in rare heart disease ATTR-CM

    Transthyretin amyloid cardiomyopathy is estimated to affect over 300,000 people worldwide

    - PMLiVE

    Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease

    Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year

    - PMLiVE

    Alnylam’s RNAi therapeutic vutrisiran recommended by CHMP for rare heart disease

    The committee has recommended the drug for both wild type and hereditary ATTR-CM

    - PMLiVE

    Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

    Cardiovascular diseases result in an estimated 17.9 million global deaths each year

    Burden of Heart Failure – Healthcare Animation

    The BriefDevelop a video that will create an emotional response and connection strong enough to inspire HCPs to consult with Heart Failure patients more proactively and promptly.The SolutionCreate an animation...

    The Good Ideas Group

    - PMLiVE

    Johnson & Johnson to acquire Abiomed in deal worth $16.6bn

    The agreement will broaden the company’s cardiovascular technologies portfolio

    - PMLiVE

    Boehringer Ingelheim and HeartBeat.bio partner to accelerate heart disease treatments

    Heart and circulatory diseases cause over 160,000 deaths in the UK each year

    Digitizing Cardiac Rehab to Capture and Retain More Patients

    Dr. Harsh Vathsangam, CEO & Co-Founder of Moving Analytics, shares his expertise on mobile health and discusses how it can be used to improve patient adherence and access to cardiac...

    Impetus Digital

    - PMLiVE

    FDA okays Amarin’s Vascepa for cardiovascular risk reduction

    Drug is on course for blockbuster sales

    - PMLiVE

    Amarin wins FDA advisory nod for Vascepa cardiovascular expansion

    Approval likely for fish-oil derived drug following speedy review

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links